Posted from: Monday, October 05, 2015 - 04:54 PM - Present

Synjardy Approved As Adjunct Treatment for Patients with Type 2 Diabetes

August 27, 2015 – The U.S. Food and Drug Administration (FDA) approved Synjardy (empaglifozin/metformin) as an adjunct to diet modification and exercise to manage blood sugar levels for patients with type 2 diabetes. Jointly developed by Eli Lilly and Boehringer Ingelheim, Synjardy is specifically indicated for adults with unstable blood sugars despite highest tolerated doses of metformin, treatment with metformin and other antidiabetic medications, or therapy with Jardiance (empagliflozin) and metformin as separate tablets. The recommended maximum dose is 12.5mg empagliflozin and 1000mg metformin to be taken twice a day.  There is currently no launch date or pricing information for Synjardy. Synjardy will carry a boxed warning about the risk of lactic acidosis when using it because it contains metformin.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Wednesday, October 16, 2019 - 05:22 AM.